West Pharmaceutical Services (NYSE:WST) Upgraded by Rothschild Redb to Strong-Buy Rating

Key Points

• West Pharmaceutical Services was upgraded to a "strong-buy" rating by Rothschild Redb, reflecting increased confidence in the company's stock.
• The company's shares opened at $257.73 and are currently projected to have a consensus target price of $318.56 from analysts, with mixed ratings overall.
• In its latest earnings report, West Pharmaceutical Services reported $1.84 EPS, exceeding expectations and showing a year-over-year revenue growth of 9.2%.

West Pharmaceutical Services (NYSE:WST - Get Free Report) was upgraded by stock analysts at Rothschild Redb to a "strong-buy" rating in a note issued to investors on Monday,Zacks.com reports.

Other equities analysts have also recently issued reports about the stock. Wall Street Zen upgraded shares of West Pharmaceutical Services from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Redburn Partners set a $311.00 price target on shares of West Pharmaceutical Services in a report on Monday. Rothschild & Co Redburn started coverage on shares of West Pharmaceutical Services in a report on Monday. They set a "buy" rating and a $311.00 price target on the stock. Barclays started coverage on shares of West Pharmaceutical Services in a report on Tuesday, June 24th. They set an "equal weight" rating and a $245.00 price target on the stock. Finally, UBS Group lifted their price target on shares of West Pharmaceutical Services from $285.00 to $320.00 and gave the company a "buy" rating in a report on Friday, July 25th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $318.56.

West Pharmaceutical Services Price Performance

Shares of NYSE:WST opened at $257.73 on Monday. The firm has a 50 day moving average of $241.77 and a 200-day moving average of $225.61. The stock has a market capitalization of $18.53 billion, a PE ratio of 38.58, a PEG ratio of 4.50 and a beta of 1.05. The company has a current ratio of 2.78, a quick ratio of 2.08 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services has a 12 month low of $187.43 and a 12 month high of $352.33.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last issued its earnings results on Thursday, July 24th. The medical instruments supplier reported $1.84 EPS for the quarter, beating the consensus estimate of $1.51 by $0.33. The company had revenue of $766.50 million during the quarter, compared to analysts' expectations of $725.11 million. West Pharmaceutical Services had a net margin of 16.48% and a return on equity of 18.43%. The business's revenue for the quarter was up 9.2% compared to the same quarter last year. During the same period in the previous year, the company earned $1.52 EPS. West Pharmaceutical Services has set its FY 2025 guidance at 6.650-6.850 EPS. On average, equities research analysts predict that West Pharmaceutical Services will post 6.62 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Zions Bancorporation National Association UT acquired a new position in West Pharmaceutical Services during the first quarter worth $25,000. CYBER HORNET ETFs LLC acquired a new position in West Pharmaceutical Services during the second quarter worth $25,000. Quarry LP acquired a new position in West Pharmaceutical Services during the first quarter worth $27,000. Vermillion & White Wealth Management Group LLC raised its holdings in West Pharmaceutical Services by 193.9% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 144 shares of the medical instruments supplier's stock worth $32,000 after buying an additional 95 shares during the last quarter. Finally, First Horizon Advisors Inc. raised its holdings in West Pharmaceutical Services by 85.0% during the first quarter. First Horizon Advisors Inc. now owns 185 shares of the medical instruments supplier's stock worth $41,000 after buying an additional 85 shares during the last quarter. Institutional investors and hedge funds own 93.90% of the company's stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.